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Recombinant human erythropoietin activates a broad spectrum of
progenitor cells. Twenty uremic patients on regular hemodialysis re-
ceived recombinant human Erythropoietin (rhEPO) in a dosage of 50
U/kg body wt (N = 9) and 80 U/kg body wt (N = 11), respectively, three
times weekly. The number of circulating hemopoietic progenitor cells
colony-forming unit-granulocyte-erythrocyte-macrophage (CFU-mix),
burst-forming unit-erythroid (BFU-E) and colony-forming-granulocyte-
macrophage (CFU-GM) in peripheral blood were assayed weekly by
means of a commonly applied in vitro clonal assay. A significant
increase of peripheral CFU-mix, BFU-E and CFU-GM could be
observed within one week of supplementation therapy in both groups.
The increase of BFU-E was followed by a rise of hematocrit within four
and three weeks, respectively, These results suggest that the stimula-
tory in vivo effect of rhEPO administered in therapeutical doses is not
restricted to the erythroid lineage but also includes progenitor cells
committed to the myeloid lineage (CFU-GM) as well as the multipotent
progenitors CFU-mix. The increment of circulating progenitor cells was
seen with a dosage of 80 U/kg body wt and 50 U/kg body wt as well.
Erythropoietin (EPO) is a circulating glycoprotein hormone
that is produced in the kidneys and stimulates bone marrow
erythroid progenitor cells to promote development into mature
red cells [1, 2]. The human gene for EPO has been recently
cloned and expressed by cultured Chinese hamster ovary cells
[3—51. Thus, recombinant human EPO (rHuEPO) has become
generally available for therapeutic application.
The supplementation with biologically active EPO offers the
possibility of an effective and continuous correction of anemia
due to end-stage renal disease. Several authors have described
a dose dependent increase of reticulocyte counts and hemato-
crit levels under treatment with rHuEPO [6—12], but there are
still only few data about the effect of rHuEPO on the earliest
erythroid progenitors as well as the non-erythroid committed
precursor cells in vivo.
The present study was undertaken to investigate the impact
of rHuEPO on peripheral progenitors burst-forming-unit ery-
throid (BFU-E), multipotent progenitor cells (CFU-mix) and
granulocyte/macrophage (CFU-GM), in patients with end-stage
renal disease and chronic hemodialysis to gain further insight in
the mechanism of this growth factor on human hemopoiesis.'
Methods
Patients
Twenty patients receiving chronic hemodialysis entered the
study to be treated with rHuEPO (Boehringer Mannheim,
Mannheim, FRG). After informed consent had been obtained
patients were randomly assigned to receive either 50 U/kg body
wt (group G 50, N = 9) or 80 U/kg body wt (group G 80, N =
11) intravenously three times weekly after each hemodialysis
session.
Uremia resulted from glomerulonephritis (N = 8), pyelone-
phritis (N = 6), analgesic abuse (N 4), and polycystic kidney
disease (N = 1). In one patient the underlying disease was
unknown. Baseline data of patients enrolled in the study are
shown in Table 1. None of the patients had received immuno-
suppressive therapy for the last three months before rHuEPO
treatment. There were no symptoms or clinical findings of
vitamin B12, iron or folic acid deficiency, nor hyperparathy-
roidism or intoxication of aluminium.
Recombinant human erythropoietin
The human erythropoietin used in this study was obtained by
DNA technology and has been developed jointly by Genetics
Institute, Cambridge, USA and Boehringer Mannheim, Federal
Republic of Germany [3]. rHuEPO was more than 98% pure,
and was formulated in a buffered saline solution. The specific
activity of rHuEPO is 173,000 U/g hormone.
Laboratory measurements
Hematological profile (Coulter counter, Coulter Electronics,
Hialeah, Florida, USA) was measured before each dialysis
session. Blood chemistry was determined once a week by a
multichannel autoanalyzer. Total protein, electrophoresis, acid-
base status and blood coagulation parameters were controlled
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Table 1. Baseline data collected during the run-in period in patients
treated with 50 or 80 U rHuEPO/kg body weight three times per
week
G50 G80
Number of patients
Age
Duration of dialysis,
months
Hematocrit, %
Corrected
reticulocyte, %
9
47 (21—67)
36 (7—107)
21.1 (18—24)
0.67 (0.3—1.7)
11
48 (27—71)
39 (5—89)
21.0 (17—25)
0.65 (0.2—1.9)
Ranges are shown in parentheses
once a month. Ferritin concentration was detected by radioim-
munoassay and controlled monthly. Reticulocyte counts were
corrected for the degree of anemia.
Peripheral progenitor cells assay
The hemopoietic progenitor cells in the peripheral blood were
analyzed weekly. Blood samples were taken 48 hours after each
injection of rHuEPO. The technique has been described de-
tailed by one of us [13].
Cell separation procedure
Twenty millilitres (ml) of peripheral blood were collected in 4
ml EDTA under sterile conditions. The light density mononu-
clear cells were obtained from the interface after sedimentation
over Ficoll-Hypaque (400 g, 40 mm, density 1.077 g/ml).
In vitro assay
Multipotent (CFU-mix) as well as committed progenitor cells
(BFU-E, CFU-GM) were assayed using a modification of the
clonal assay described by Messner et al [14, 15]. Each plate
contained 0,9% methylcellulose, 30% fetal calf serum, 10%
bovine serum albumin (Behring, FRG), 1 pi per ml erythropoi-
etin (Toyobo,) alpha-thioglycerol (10 mol per liter), 5% phyto-
hem-agglutinine-leucocyte-conditioned medium and Iscove' S
modified Dulbecco's medium (Gibco, Grand Island, New York,
USA).
Peripheral blood mononuclear cells were plated in quadrupli-
cates at 2.5 x iø per ml.
Alter a culture period of 14 days (at 37°C with 5% CO2 and
full humidity) cultures were examined under an inverted micro-
scope. Aggregates with at least 40 translucent, dispersed cells
were counted as CPU-GM. Bursts containing more than 100 red
colored cells were scored as BFU-E. CPU-mix were identified
by their heterogenous composition of translucent and hemoglo-
binized cells. Individual colonies suspected as CFU-mix were
picked, transferred to glass and stained by May-Gruenwald-
Giemsa for cytological examination under light microscope.
The clonal nature of mixed colonies was confirmed by the linear
relationship between the numbers of colonies.
Calculation of the peripheral blood progenitors
The total number of mononuclear cells per ml of peripheral
blood was determined by multiplying the total number of white
cells by the percentage of mononuclear cells in the differential
count. The mononuclear cell fraction consisted of immature
myeloid forms, monocytes and lymphocytes circulating in the
peripheral blood. The total numbers of progenitor cells per ml
of peripheral blood were determined by multiplying the number
of CFU-GM, BPU-E or CFU-mix /l0 MNC by the total
number of MNC per ml of peripheral blood. The normal ranges
for the hemopoietic progenitor cells were obtained from 50
healthy volunteers.
Determination of concentration of tumor necrosis-a (TNF-a)
and interferon-y (INF-y) in serum
TNF-a and INF-y concentration in serum was determined by
commercially available immunoradiometric assay kits (TNP-
a-IRMA and INF-gamma-IRMA, Medgenix', Fleurus, Bel-
gium). Values were assayed prior and four weeks after initiation
of rHuEPO therapy.
Normal values were obtained from 50 healthy blood donors
and found to be 5.7 3.5 pglml for TNP-a, whereas INF-y
were not detectable in healthy volunteers.
Statistical analysis
Statistical analysis was carried out using the Mann-Whitney
U-test [16]. The level of significance was set at P < 0.05. All
values are expressed as means and standard error (SE).
Results
Since none of the patients had their therapy discontinued,
data for evaluation could be obtained from all 20 patients. The
frequency of dialysis sessions remained constant in all patients.
The injection of rHuEPO was well tolerated in all cases without
any problems of local or systemic intolerance.
Mild side effects were observed in eight patients. Worsening
of hypertension that needed increase of antihypertensive treat-
ment was detected in two patients of group G 50 and in three
patients in group G 80. One patient from each group complained
about headache, and pain in the joints. Influenza-like symptoms
occurred in one patient of group G 80 and were transitory.
Hematological findings and iron status
Reticulocyte count started to rise within the second week in
both groups, and was followed by an increase of hematocrit
during the third week in group G 80 and after four weeks of
rHuEPO treatment in group G 50.
The median percent increment of hematocrit per week was
1% in group G 50 and 1.2% in group G 80. No significant change
of mean corpuscular volume (MCV) could be detected.
Platelet number increased moderately under rHuEPO ther-
apy by an average of 7% in both groups, but true thrombocy-
tosis was observed in none of the patients. The increase of
platelet count was not accompanied by any complication, such
as thrombosis of the arteriovenous fistulas or other thrombo-
embolic events. The increase of thrombocyte count was not
intercorrelated with iron deficiency. White blood counts (WBC)
and differential counts remained unaffected.
Along with the increase of hematocrit a considerable de-
crease of serum iron and ferritin levels was observed, necessi-
tating iron supplementation in four patients of group G 50 and
five patients in group G 80.
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10 Fig. 2. Effect of treatment with rHuEPO on
the concentration of multipotential
hemopoie:ic progenitors CFU-MIX in the
peripheral blood of patients with anemia of
chronic renal failure, Symbols are: ()80
U/kg body wt 3x/week (N = 11); (.---) 50 UI
kg body wt 3x/week (N = 9).
Blood and serum chemistry
There was no increase of potassium level during EPO ther-
apy. The median serum concentration of urea and creatinine did
not change significantly. Furthermore no change was found for
bilirubin, liver enzymes or lactatedehydrogenase (LDH). Se-
rum protein concentration and electrophoresis remained con-
stant.
Peripheral progenitor cells
The concentration of hemopoietic progenitor cells BFU-E in
peripheral blood increased significantly from subnormal levels
to normal range within one week of treatment in both treatment
groups. The rise was most pronounced during the first week and
the concentration remained within normal ranges up to the end
of the observation period (Fig. 1).
The number of CFU-mix showed a similar course with a
marked increase from subnormal to normal ranges within one
week of the two rHuEPO supplementation regimens (Fig. 2).
The concentration of CFU-GM proved to be low but within
normal ranges prior to rHuEPO therapy. rHuEPO therapy lead
to a significant rise in both groups of CFU-GM (Fig. 3).
One patient acquired bacterial pneumonia during rHuEPO
treatment. The onset of clinical symptoms was accompanied by
a marked decrease of BFU-E which was followed by a reduc-
tion of hematocrit with a delay of two weeks, although therapy
with rHuEPO was continued. Antibiotic therapy was started
and the patient recovered from respiratory infection within 20
days. The counts of BFU-E as well as the red blood count
returned to levels measured before infection after a further two
and four weeks, respectively (Fig. 4).
Patients who developed iron deficiency showed a decrease of
BFU-E count one week prior to a marked fall of hematocrit, as
shown for one patient in Figure 5.
In six patients of group G 50 we changed therapy of 50 U/kg
body wt three times weekly to 150 U/kg body wt once weekly.
The number of BFU-E initially showed a small increase above
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Fig. 1. Effect of treatment with rHuEPO on
the concentration of erythroid progenitors
BFU-E in the peripheral blood of patients
with anemia of chronic renal failure. Symbols
are: () 80 U/kg body wt 3 x/week (N = 11);
(----) 50 U/kg body wt 3 X/week (N = 9).
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Fig. 4. Effect ofa bacterial infection on the
concentration of e,ythroid progenitors BFU-E
in the peripheral blood of a patient with
anemia of chronic renal failure during
continuous rHuEPO treatment. Symbols are:() BFU-E cells; (----) hematocnt; (")
absolute count of reticulocytes.
Fig. 5. Effect of a iron deficiency on the
concentration of erythroid progenitors BFU-E
in the peripheral blood of a patient with
anemia of chronic renal failure during
continuous rHuEPO treatment. Symbols are:
(—) BFU-E cells; (----) hematocnt; ()
absolute counts of reticulocytes.
the baseline levels after two days, but it consequently de-
creased significantly below baseline levels on days four and six.
By altering therapy again to 50 U/kg body wt thrice weekly, the
concentration of BFU-E returned to previous values with a
delay of one week (Fig. 6).
Concentration of TNF-a and INF-y in serum
Concentrations of TNF-cr in serum was found to be 7.1 3.9
pg/ml (G 50) and 6.8 3.3 pg/ (G 80) prior to rHuEPO therapy.
Mter application of rHuEPO, TNF-a concentrations were 6.9
3.6 pg/mi in group G 50 and 7.0 3.1 pg/mI in group G 80.
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INF-y was neither detectable prior to nor after initiation of
rHuEPO therapy.
Discussion
EPO is a glycoprotein hormone which regulates the rate of
proliferation and differentiation of erythroid precursors in the
bone marrow [1]. It is part of a complex feedback system which
ultimately adjusts the red cell mass to the demand of oxygen by
the tissues. All circumstances of changes in EPO production
reflect a general regulatory principle that can be summarized in
that increased levels of EPO are accompanying reduced oxygen
supply or increased oxygen demand, while suppressed levels of
EPO are typical for conditions with increased oxygen supply or
reduced oxygen demand.
EPO levels in anemic uremic patients are inappropriately low
for their degree of anemia [17]. Although the pathophysiology
of anemia due to end-stage renal failure is supposed to be
multifactoral, the relative EPO deficiency appears to play the
preponderant role in its genesis, since administration of EPO
can correct the anemia of these patients [7]. Up to 50% of
chronically hemodialyzed patients require periodic red cell
transfusions to prevent symptoms of severe hypoxia [18]. But
transfusion therapy is transient and fraught with the risk of
infection, hemosiderosis and the development of cytotoxic
antibodies and further erythroid suppression [19]. The availabil-
ity of recombinant human Erythropoietin (rHuEPO) by molec-
ular biology [3—5] not only offered the opportunity of correcting
renal anemia [6—10] but has provided better understanding of its
pathophysiological circumstances.
In agreement with the findings reported by others ([6—10], our
results showed that administration of rHuEPO in a dosage of 50
U/kg body wt or 80 U/kg body wt thrice weekly exerts an
effective stimulus on red cell production in patients on regular
hemodialysis. An increase of mean hematocrit to 35% and mean
hemoglobin concentration to 10.9 g/dl was achieved within 10
weeks of treatment in both groups.
Iron depleted patients were found to have a hampered
response to rHuEPO therapy [7]. Therefore, close monitoring
of iron and ferritin levels are indicated under rHuEPO therapy
and iron supplementation is necessary in many cases. Our
experiences showed that the decrease in serum ferritin concen-
tration was accompanied by a fall of circulating BFU-E in
peripheral blood, thus representing an early indicator of iron
deficiency.
After good initial response to rHuEPO therapy, cases of
temporary nonresponse have been associated with bacterial
infections [20]. In our study one patient showed a diminished
response to rHuEPO supplementation during bacterial respira-
tory infection. Prior to pneumonia and after appropriate antibi-
otic treatment he responded to rHuEPO well. The serum
ferritin levels remained within the normal range during that
period, and there were no signs of aluminium intoxication of
hyperparathyroidism. With regard to the blunted response of
patients to rHuEPO therapy during bacterial infections poten-
tial interactions with other cytokines released by the activation
of the immune system might be discussed. The effect of
lymphokines such as tumor necrosis factor (TNF) and interfer-
on-gamma (INF-y) on early and mature erythroid progenitor
cells has been investigated with conflicting results. A profound
stimulatory effect of TNF on early erythroid compartments has
been observed in normal and leukemic mice [21]. An inhibitory
effect of TNF and INF-y on erythropoiesis has been found in
vitro [22—27] and in normal mice as well [27]. In a clinical study
a decrease of hemoglobin in cancer patients has been associated
with TNF treatment [28]. We have found normal levels of TNF
and INF-y in patients on hemodialysis treated with rHuEPO
and who were free from infection, thus indicating that the
stimulatory hemopoietic effect of rHuEPO is not mediated by
these lymphokines. The concentration of these cytokines in the
very patient during the period of pneumonia has not been
measured but probably they would have been increased. Nev-
ertheless, a high concentration of TNF and INF-y as a cause of
depressed response of circulating BFU-E to rHuEPO would be
in conifict with the results reported by Johnson, Chang and
Furmanski [21], who have found a stimulation of BFU-E by
administered TNF. But the immunologic reactions resulting
from a systemic infection are definitely more complex than can
be mimicked by the application of single recombinant cyto-
kines. Thus the above discussed mechanism of hampered
rHuEPO response during bacterial infection remains highly
speculative and deserves further investigation.
In the present study we could not find a significant increase in
platelet counts. In two clinical trials [6, 7] similar results have
been obtained. Bommer et al however, pointed out an increase
of the median thrombocyte count during rHuEPO therapy [8,
10]. A possible influence on megakaryocytic committed cell
lineage by rHuEPO had been analyzed in vitro with contradict-
ing results. No promotion of megakaryocytic differentiation
could be detected with human bone marrow cells [29, 30],
whereas in contrast stimulatory activity had been obtained by
others [31].
The principle target cells of EPO are the CFU-E, which is an
immediate precursor of the differentiated normoblast and is
known to be highly sensitive to EPO. It gives rise to single
colonies of 8-49 erythroblasts [32]. EPO acts to a far lesser
extent on earliest erythroid progenitors, BFU-E. A stimulating
activity of EPO on BFU-E in tissue culture has been reported
[33, 34] and EPO has induced DNA synthesis in human marrow
BFU-E in vitro [35]. It enhances 45Ca2 and '4C-2-deoxy-
150
I iI 50 50 U EPO/kg body wt
500—
400—
300-
200—
100—
I I I I I I I I
0 2 4 6 8 10 12 l4days
P < 0.05
Fig. 6. Effect of different dosages and dUferent intervals of rHuEPO on
the concentration of erythroid progenitors BFU-E in the peripheral
blood of six patients with anemia of chronic renal failure.
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glucose uptake [36] and stimulates RNA synthesis in erythroid
progenitors [37] in vitro. Studies in experimental animals ren-
dered acutely anemic or injected with EPO showed a lack of
change in the early erythroid progenitors pool [38—40]. The
multipotent hemopoietic precursor CFU-mix has the capacity
to form erythrocytes, myeloid cells and monocytes as well. No
effect of EPO on this progenitor cells has been described so far.
The present study points out a profound increase not only of
BFU-E but also of CFU-mix and CFU-GM in the peripheral
blood. But these observations cannot be taken as an direct
indicator of a stimulatory activity of rHuEPO to the marrow
pool. It might be interpreted as an efflux of cells from marrow
compartments to peripheral blood as well. Two reports inves-
tigating the effect of rHuEPO on marrow progenitors in vivo
have been published recently, and have outlined an increase of
the concentration of non-erythroid progenitors in human bone
marrow [30, 411. These results encourage us to conclude that
the observed expansion of the peripheral blood progenitor cell
compartment is not the effect of redistribution but reflects a
direct or at least indirect stimulation of the precursors in the
marrow pool.
In contrast to the changes of concentration of peripheral
progenitor cells the differential blood count remained unaf-
fected. This lack of change in peripheral white cell count
remains unclear as well. Granulopoiesis might be under nega-
tive feedback control of differentiated cells [32], but the lack of
additional hemopoietic growth factors must be considered as a
possible reason for the unchanged white blood count.
The precise underlying physiological mechanisms responsi-
ble for the stimulation of non-erythroid precursor cells remain
unclear. We cannot say whether the multilineage response of
rHuEPO is a direct one or is mediated through an action of
accessory or stromal cells, or is mediated by hemopoietic
growth factors liberated by rHuEPO application. With regard to
the unphysiologically high concentration and the pulsatile form
of application, a direct or indirect stimulation of rHuEPO is
feasible. In this context it has been suggested that human bone
marrow responds to therapeutic doses of rHuEPO as an organ
rather than by a selective expansion of the erythroid line and
the activation of stem cells results in an increase of all commit-
ted progenitor cells [41].
In conclusion, our data showed that rHuEPO increased not
only the erythroid committed hemopoietic precursor cells but
also CFU-GM and CFU-mix in the peripheral blood. These
results might be interpreted as a stimulation of bone marrow
progenitors. With regard to the rich diversity of hemopoietic
cellular interaction and actions of hemopoietic growth factors,
the underlying mechanism must remain speculative. Further
investigations are necessary to clarify the mechanism as well as
a potential therapeutic value of these observation in states of
disturbed hemopoiesis.
Reprint requests to Felix Stockenhuber, M.D., Department for Renal
Disease and Haemodialysis, Vienna University School of Medicine,
Lazarettg. 14, A-1090 Vienna, Austria.
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